Pharmaceutical company Galderma (UK) Limited has begun a review of its distribution arrangements and announced plans to appoint one preferred distributor for its Azzalure and Restylane brands.
Galderma states that the
preferred company will attain a contract to service all customers who purchase
Azzalure and Restylane in the UK and ROI, and
will be supported to deliver a more customer-centric proposition, including enhanced
levels of tailored support for healthcare professionals. While there will still
be a preferred distributor, other distributors will meanwhile continue to be
able to purchase Galderma products and services.
“By refining our distribution
model, we believe that we can enrich the overall relationship with our
customers, offering healthcare professionals an enhanced level of tailored
support as well as a continued, reliable supply of our products,” said Toby
Cooper, medical solutions business unit head for Galderma UK and Ireland.
Cooper added, “More than ever, healthcare professionals need to have confidence
in the quality of the outcomes they can deliver. They need a supplier they
trust, providing them with products and support they know they can rely on.”
